Cargando…
Nebulised heparin as a treatment for COVID-19: scientific rationale and a call for randomised evidence
Nebulised unfractionated heparin (UFH) has a strong scientific and biological rationale and warrants urgent investigation of its therapeutic potential, for COVID-19-induced acute respiratory distress syndrome (ARDS). COVID-19 ARDS displays the typical features of diffuse alveolar damage with extensi...
Autores principales: | van Haren, Frank M. P., Page, Clive, Laffey, John G., Artigas, Antonio, Camprubi-Rimblas, Marta, Nunes, Quentin, Smith, Roger, Shute, Janis, Carroll, Mary, Tree, Julia, Carroll, Miles, Singh, Dave, Wilkinson, Tom, Dixon, Barry |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7374660/ https://www.ncbi.nlm.nih.gov/pubmed/32698853 http://dx.doi.org/10.1186/s13054-020-03148-2 |
Ejemplares similares
-
Inhaled nebulised unfractionated heparin (UFH) for the treatment of hospitalised patients with COVID-19: A randomised controlled pilot study()
por: DeNucci, Gilberto, et al.
Publicado: (2023) -
Can nebulised HepArin Reduce morTality and time to Extubation in patients with COVID‐19 Requiring invasive ventilation Meta‐Trial (CHARTER‐MT): Protocol and statistical analysis plan for an investigator‐initiated international meta‐trial of prospective randomised clinical studies
por: van Haren, Frank M. P., et al.
Publicado: (2022) -
A phase 1 trial of nebulised heparin in acute lung injury
por: Dixon, Barry, et al.
Publicado: (2008) -
Heparin, Low Molecular Weight Heparin, and Non-Anticoagulant Derivatives for the Treatment of Inflammatory Lung Disease
por: Shute, Janis Kay
Publicado: (2023) -
Nebulized Heparin Attenuates Pulmonary Coagulopathy and Inflammation through Alveolar Macrophages in a Rat Model of Acute Lung Injury
por: Chimenti, Laura, et al.
Publicado: (2017)